Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

48
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
48
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

509
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
509
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

22
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
22
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

724
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
724
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

34
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
34
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

31
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
31

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Formulated curcumin exerts potent anti-influenza activity by inhibition of Akt activation and viral genome replication.

Intervirology·2026
Same author

PP4 modulates macrophage-neutrophil crosstalk to restrict CCL5 -driven NETosis in sepsis.

Redox biology·2026
Same author

Prevention of Heart Failure Induced by Doxorubicin with Early Administration of Dexrazoxane (PHOENIX Study): dose response and time course of dexrazoxane-induced degradation of topoisomerase 2b.

Cardio-oncology (London, England)·2025
Same author

CYLD links the TRAF6/sNASP axis to TLR4 signaling in sepsis-induced acute lung injury.

Cellular and molecular life sciences : CMLS·2025
Same author

Microglia-Mediated Synaptic Dysfunction Contributes to Chemotherapy-Related Cognitive Impairment.

Journal of neurochemistry·2025
Same author

Lactate: an intracellular metabolite regulates cell cycle progression.

Life metabolism·2025

Related Experiment Video

Updated: Sep 12, 2025

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

4.8K

ANTHRACYCLINE-INDUCED CARDIOTOXICITY: MECHANISM AND PREVENTION.

Edward T H Yeh1, Hui-Ming Chang1

  • 1Little Rock, AR.

Transactions of the American Clinical and Climatological Association
|August 7, 2025
PubMed
Summary

Topoisomerase 2b is the key cause of anthracycline-induced heart failure in cancer patients. Targeting this enzyme with dexrazoxane may prevent cardiotoxicity without compromising chemotherapy effectiveness.

More Related Videos

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

9.9K
Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

7.5K

Related Experiment Videos

Last Updated: Sep 12, 2025

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

4.8K
A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

9.9K
Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

7.5K

Area of Science:

  • Cardiology
  • Oncology
  • Molecular Biology

Background:

  • Anthracyclines are vital cancer drugs but cause dose-dependent cardiotoxicity.
  • Cardiomyocytes express topoisomerase 2b, which is implicated in anthracycline-induced damage.

Purpose of the Study:

  • To identify the specific topoisomerase isoform mediating anthracycline cardiotoxicity.
  • To evaluate dexrazoxane's novel mechanism and therapeutic potential for preventing heart failure during cancer treatment.

Main Methods:

  • Utilized genetic models to delete topoisomerase 2b in cardiomyocytes.
  • Investigated the effects of anthracyclines on DNA damage, reactive oxygen species (ROS), and mitochondrial function.
  • Examined dexrazoxane's effect on topoisomerase 2b degradation.

Main Results:

  • Deleting topoisomerase 2b in cardiomyocytes prevented anthracycline-induced DNA damage, ROS production, mitochondrial dysfunction, and heart failure.
  • Dexrazoxane selectively induces degradation of topoisomerase 2b, sparing topoisomerase 2a.
  • Preclinical studies support dexrazoxane pretreatment to mitigate cardiotoxicity.

Conclusions:

  • Topoisomerase 2b is the critical mediator of anthracycline-induced cardiotoxicity.
  • Dexrazoxane offers a promising strategy to prevent heart failure during anthracycline therapy by selectively degrading topoisomerase 2b.
  • The PHOENIX trial is investigating this protective approach.